CNTB · Insider Trading
Connect Biopharma Holdings Limited Ordinary Shares
Every open-market purchase and sale reported by CNTB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-01 | Kleanthis Gabriel Xanthopoulos | Director | A | +5,000 | — |
| 2026-10-01 | Jean I Liu | Director | A | +8,984 | — |
| 2026-07-01 | Jean I Liu | Director | A | +6,718 | — |
| 2026-07-01 | Kleanthis Gabriel Xanthopoulos | Director | A | +3,738 | — |
| 2026-06-02 | James Huang | Director | Buy | +150,000 | +$371.61K |
| 2026-04-02 | Jean I Liu | Director | A | +5,061 | — |
| 2026-04-02 | Kleanthis Gabriel Xanthopoulos | Director | A | +2,816 | — |
| 2026-04-01 | James Huang | Director | Buy | +1,160,000 | +$4.00M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| James Huang | Director | 13,310,000 | $10.02M |
| Kleanthis Gabriel Xanthopoulos | Director | 91,554 | $68.93K |
| Jean I Liu | Director | 20,763 | $15.63K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CNTB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.